Gatti L, Zuco V, Zaffaroni N, Perego P
Glucagon-like peptide 1 (GLP-1) acts as an incretin hormone and anorexigenic neuropeptide, prompting the successful and ongoing development of GLP-1-based therapies for type 2 diabetes and obesity 1,2
Patients typically receive semaglutide as a once-weekly injection , which makes it convenient but also requires understanding how the body may react soon after administration
Contrave is an approved weight-loss medication available by prescription only
Audit nutrition per serving
In rare cases, semaglutide may be linked with Gallbladder problems, kidney injury, Pancreatitis, or worsening Diabetic Retinopathy